MDACC Study No:2011-0142LEUKEMIA ( NCT No: NCT01109069)
Title:A Long-Term Safety Study of Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and
Chronic Lymphocytic Leukemia
Principal Investigator:William G. Wierda
Treatment Agent:PCI-32765
Study Status:Closed
Study Description:The goal of this study is to learn if PCI-32765 (also called Ibrutinib or
IMBRUVICA®) given 1 time a day is tolerable by looking at the side effects for
patients that have taken PCI-32765 in a previous study. Researchers also want
to learn if PCI-32765 can help to control the disease.

PCI-32765 is a type of drug called a kinase inhibitor. Kinases are proteins
inside cells that help cells live and grow. The specific kinase blocked by
the study drug is believed to help blood cancer cells live and grow. By
blocking the activity of this specific kinase, it is possible that the study
drug may kill the cancer cells or stop them from growing.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:N/A
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics LLC an AbbVie Company
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults